Purpose: To determine the association of serum insulin-like growth factor 1 (IGF-1) and vitamin D levels with cognition status in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 173 patients with T2DM were recruited and divided into mild cognitive impairment (MCI) group (n ¼ 94) and normal cognition (NC) group (n ¼ 79). Levels of IGF-1 and 25(OH)D were measured and compared, and the correlations among IGF-1, 25(OH)D, and cognitive function were analyzed. Results: Insulin-like growth factor 1 and 25(OH)D levels significantly decreased in MCI group than those in the NC group (both P < .001). Multiple stepwise regression analysis revealed that IGF-1 (b ¼ .146, P < .001) and 25(OH)D (b ¼ .199, P < .001) independently predicted Montreal Cognitive Assessment (MoCA) scores. Partial least square regression showed that contributions of both 25(OH)D (P < .001) and IGF-1 (P < .001) to MoCA scores were significant, while no cross-effect was observed between them (P ¼ .714). Conclusions: Low serum IGF-1 and 25(OH)D levels may separately predict poor cognitive performance in patients with diabetes.
Introduction
Type 2 diabetes mellitus (T2DM) is a growing epidemic worldwide, with considerable impact on health-care expenditures, morbidity, and mortality. It has been increasingly associated with mild cognitive impairment (MCI) and dementia. [1] [2] [3] [4] Mild cognitive impairment, which is considered a transitional stage between normal aging and dementia, was increasingly concerned because of a high risk of developing to Alzheimer disease (AD) at a rate of 10% to 15% per year. 5 Epidemiological and basic science studies have suggested a possible shared pathophysiology between T2DM and AD. 6 Hence, cognitive dysfunction was also considered a chronic neurological complication of diabetes. However, underlying mechanisms of diabetes-related cognitive dysfunction are complicated and not yet been fully understood.
Insulin-like growth factor (IGF)-1, which is structurally related to insulin, is a polypeptide hormone exerting effects in the differentiation, proliferation, and regulation of various central and peripheral tissues. 7, 8 (p1) Previous studies have revealed that serum IGF-1 levels change in patients with AD, 9 that low levels of IGF-1 can be associated with worse cognitive function in older adults, 10 and also predict cognitive decline in AD. 11 However, data on this topic are inconsistent. Results of a systematic review 12 indicated that IGF-1 concentrations do not confer additional diagnostic information for those with cognitive decline. Increasing evidence suggests that vitamin D may affect the synthesis and/or activity of IGF-1. [13] [14] [15] The interplay between vitamin D and IGF-1 is complicated and occurs at both endocrine and paracrine/autocrine levels. Several studies have also acknowledged the association between vitamin D deficiency with higher risk of MCI and dementia. 16, 17 However, the levels of IGF-1 and vitamin D and their correlations with the cognitive dysfunction due to diabetes have been little investigated. This study was designed to assess the association between IGF-1, 25(OH)D levels, and cognitive function in patients with T2DM. (2) as reported, the decline in cognitive function relative to the previous capacity has declined in the past year (Clinical Dementia Rating score of 0.5); (3) through clinical evaluation, cognitive disorder were evidenced (impairment in memory or some other cognitive field); (4) short of major repercussions in daily life; and (5) the absence of dementia.
Material and Methods

Patients
Exclusive criteria are as follows: (1) diabetic ketoacidosis, hypoglycemia coma, hypertonic glucose coma, and other acute complications of diabetes; (2) cerebrovascular accident, infection in central nervous system, stroke, cerebral hemorrhage, or other clinical evidences of central nervous damages; (3) visual and auditory resolution deficiencies; (4) Parkinson disease, systemic disease such as malignancy, severe anemia; thyroid disease, Cushing syndrome, drug abuse or dependence history, and depression (within 3 months); anticoagulants; antiParkinson disease drugs, benzodiazepines and barbiturates, antiepileptic drugs, and so on were used in the first 3 months of screening; and (5) patients of long-term bedridden or cannot take care of themselves.
This study was carried out in accordance with the Declaration of Helsinki (2013) of the World Medical Association. The institutional ethical review board approved the study and all participants have given written informed consents.
Clinical Evaluation
Demographic characteristics including age, sex, education levels, smoking history, alcoholism, insomnia, sun exposure status, physical exercise conditions, and history of hypertension and/or dyslipidemia were collected. Physical measurements including body mass index, waist circumference, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were collected using a standard beam balance scale. Patients with SBP !140 mm Hg, or DBP !90 mm Hg, respectively, or current use of antihypertensive medications were identified as having a history of hypertension. Medication use situations (including antidiabetic medications, antiplatelet medications, lipid-lowering medications, and antihypertensive medications) were also obtained through questionnaires.
Laboratory Methods
Blood samples were obtained from patients by venipuncture after an overnight fast (!8 hours) and tested within 60 minutes. Serum 25(OH)D, including 25(OH)D 2 and 25(OH)D 3 , thyroidstimulating hormone (TSH), C-peptide (C-P), and parathyroid hormone (PTH) were tested by electrochemiluminescence immunoassay (Cobas 6000 analyzer; Switzerland, Roche). Insulin-like growth factor 1 was measured by chemiluminescence method (IMMULITE 1000; USA DPC). Fasting blood glucose, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, serum creatinine (1 mg/dL ¼ 88.41 mmoI/L), uric acid, blood urea nitrogen, calcium (Ca), and phosphorus (P) were quantified enzymatically (Cobas 8000 C701 C502 auto chemistry analyzer; Roche); HbA1c was measured by highperformance liquid chromatography (HLC-723G7 analyzer, TOSOH, Japan Ultrasonography of carotid arteries. We located the thickest site of the carotid artery intima-media and to measure the thickness at sites 1 cm downstream using color Doppler ultrasound (Sequoia scanner; SIEMENS, Germany). Mean C-IMT (carotid intima-media thickness)
Statistical Analyses
Normal test by Kolmogorov-Smirnov test was applied on all continuous data. Since TSH concentrations were not normal distribution, they were log-transformed for analyses. Independent t test was applied to compare measurement data, and qualitative data were analyzed by thew 2 test between 2 groups. Associations of MoCA scores, IGF-1, 25(OH)D, and other variables were analyzed using Pearson/Spearman rank correlation analysis. A prediction model for correlations of variables and MoCA scores was created using multiple linear regressions. Standard least square regression is used to estimate the contribution of dependent variables to the cognitive function (MoCA scores). JMP 14 (SAS institute Inc) and Statistical Package for the Social Science (SPSS version 19.0, IBM) were applied in this study. Data were expressed in the tables and text as mean (standard deviation) or median (25%-75%). A 2-sided P <.05 was considered to be statistically significant.
Results
As shown in Table 1 , the proportion of injection of insulin was higher, and use of oral hypoglycemic drugs was lower in MCI group than those in normal cognition (NC) group. No other differences were observed in medication use between patients in NC group and MCI group. The clinical characteristics of both groups are shown in Table 2 . Comparing with the NC group, patients with MCI had a longer duration of diabetes, fewer education years, less sun exposure, and their SBP, HbA1c, TC, HDL-C, PTH, calcium, and mC-IMT were elevated, and C-P, TG, eGFR, 25(OH)D, IGF-1, and MoCA scores were decreased (P < .05). All the components in MoCA scales significantly decreased in MCI group than in NC group (P < .05).
Univariate analysis of MoCA scores, 25(OH)D, and IGF-1 with other characteristics were listed in Table 3 . Montreal Cognitive Assessment scores were positively associated with education years, smoking history, insomnia, TG, eGFR, and C-P and inversely associated with duration of DM, hypertension history, insulin use, oral hypoglycemic drugs use, SBP, HbA1c, TC, HDL-C, 25(OH)D, IGF-1, PTH, and mC-IMT. 25(OH)D levels were positively associated with education, sun exposure, alcoholism, TG, and IGF-1 and inversely associated with sex, duration of DM, insulin use, oral hypoglycemic drugs use, HbA1c, TC, and PTH levels. The levels of IGF-1 were positively associated with education, 25(OH)D, and TG and inversely associated with age, duration of DM, hypertension history, insomnia, oral hypoglycemic drugs use, HbA1c, TC, and PTH.
Correlations among MoCA scores, IGF-1, 25(OH)D, and cognitive domain scores are presented in Table 4 . Levels of IGF-1 and 25(OH)D were positively correlated with all the domains of the cognitive function (using MoCA scales; P < .05).
After adjusting for age, sex, duration of DM, and education, the regression model included hypertension history, smoking history, insulin use, oral hypoglycemic drugs use, insomnia, SBP, HbA1c, TC, TG, HDL-C, eGFR, 25(OH)D, IGF-1, PTH, Ca, C-P, and mC-IMT as covariates and revealed that 25(OH)D, IGF-1, SBP, C-P, and mC-IMT were independent predictors of MoCA scores (R 2 ¼ 0.491; Table 5 ). Since 25(OH)D was positively associated with IGF-1 in this study, standard least square regression was applied to estimate the contributions of IGF-1 and 25(OH)D to MoCA score. The results showed that the main effects of both 25(OH)D and IGF-1 were significant, while no cross-effect was observed between them (Table 6 and Figure 1A -C).
Discussion
The prevalence of CI and its correlation with diabetes has been greatly underestimated. [19] [20] [21] Screen tools and interventions that can prevent, slow, or reverse the progressive of these neurodegenerative illnesses are needed. Mild cognitive impairment is a screening tool with high sensitivity which can be applied to divide patients into MCI and normal-cognition groups in the diabetic population. 22 The current study shows that levels of IGF-1 decreased in MCI group and positively associated with cognitive function according to the MoCA scales in patients with T2DM. Insulin-like growth factor 1 is considered an essential neurotrophic factor and plays a critical role in nervous system homeostasis, 23 which can be correlated with cognitive function in older population. 24 Nevertheless, whether its levels are positively or negatively correlated with cognitive function is a debatable point. A study by Tumati et al 10 revealed that both increased and decreased concentrations of IGF-1 may be associated with cognitive dysfunction in middle-aged and older men. Our data are consistent with studies in people without diabetes 11, 25, 26 that those with higher levels of IGF-1 gain higher scores in multiple domains and they independently predict better cognitive function. Abbreviations: C-P, C-peptide; IGF-1, insulin-like growth factor 1; mC-IMT, mean carotid intima-media thickness; MoCA, Montreal Cognitive Assessment; SBP, systolic blood pressure.
Vitamin D deficiency is very common in T2DM. 27 Vitamin D exerts some effect in neuroprotection and regulation in the central nervous system. [28] [29] [30] [31] It has been reported 13, 32, 33 that IGF-1 plays a role through changes in vitamin D activation, and 1,25(OH) 2 D can regulate IGF-1 axis genes the other way round. However, it is unknown whether they play joint effects on cognitive protection. In the current study, results of partial least square regression showed that IGF-1 and 25(OH)D significantly contributed to MoCA scores, which means they separately influenced the cognitive function. However, although IGF-1 and 25(OH)D correlated with each other, they had no joint effect on MoCA scores (P ¼ .714). Yet, interventional studies haven't shown a clear benefit from vitamin D supplementation. 34 There might be likely a therapeutic age/time window relevant to the development of disease and therefore vitamin D therapy.
Abnormal PTH levels exert some effect in neuronal calcium dysregulation, hypoperfusion and disrupted neuronal signaling. However, whether PTH levels predict a poor cognitive function in patients with diabetes is controversial. A study by Kalaitzidis et al 35 suggested that increased serum PTH levels are associated with cognitive dysfunction in patients with chronic kidney disease and hypertension. But previous evidence offers weak support for a link between cognition and dementia due to the paucity of high-quality research in this area. 36 Additionally, a recent Atherosclerosis Risk in Communities cohort study of a 20 years' follow-up has found no association of higher mid-age PTH levels with old-age prevalent diagnosed dementia, 37 which did not support an independent influence of PTH on cognitive decline. Our study indicated that PTH increased in MCI group and was inversely associated with cognitive function in patients with diabetes. But it was not independently correlated with MoCA scores. Since 25(OH)D levels independently predicted MoCA scores, we speculated that the strong inverse association between PTH and 25(OH)D indirectly resulted in the inverse correlation between PTH and MoCA scores, but the observation deserves further cohort study.
Limitations
(1) Self-reported data including history of hypertension, dyslipidemia, and duration of DM may cause recall bias. (2) All results of this study were from a small sample aged from 51 to 73 years, which cannot represent all patients with diabetes. (3) The diagnostic criteria in this study were only MoCA scores, which might lead to bias, while some other investigators carried out their studies with several cognitive scales including Digit Span Test, Verbal Fluency Test, activity of daily living scale, and so on. 4. This is a cross-sectional study, which limits causal inference. In addition, some potential confounders (ie, diabetes duration, C-P, carotid IMT, other diabetic complications, etc) may cause bias of the results. Further investigation with well-matched case-control cohort, more cognitive scales, and the MCI progression follow-up are warranted to verify these preliminary results and explore their clinical significance.
In summary, our current study showed that low levels of IGF-1 and 25(OH)D were associated with MCI in patients with diabetes, and IGF-1 levels were positively associated with serum levels of 25(OH)D. The decreasing of both IGF-1 and 25(OH)D may independently predict MCI. Although this study was not designed to explore the precise mechanism by which vitamin D and IGF-1 modulate cognitive dysfunction, we preliminary studied the associations between these 2 hormones on MCI in patients with diabetes. This study suggested that both 
